Expression and significance of HMGB1 in patients with sepsis and effects on prognosis

References

• An S, Qin B, Lu G, Fan Y, Jia B. 2018. Effect of high mobility group protein B1 on the immune function of regulatory T cells. J Pract Med. 34(17):2912–2915.
   Google Scholar
• Chalmin F, Bruchard M, Vegran F, Ghiringhelli F. 2018. Regulation of T cell antitumor immune response by tumor induced metabolic stress. Cell Stress. 3(1):9–18. doi: https://doi.org/10.15698/cst2019.01.171
   Google Scholar
• Cohen J. 2002. The immunopathogenesis of sepsis. Nature. 420(6917):885–891. doi: https://doi.org/10.1038/nature01326
   PubMed Web of Science ®Google Scholar
• Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, et al. 2008. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 34(1):17–60. doi: https://doi.org/10.1007/s00134-007-0934-2
   PubMed Web of Science ®Google Scholar
• Fan L, Strasser-Weippl K, Li JJ, St Louis J, Finkelstein DM, Yu KD, Chen WQ, Shao ZM, Goss PE. 2014. Breast cancer in China. Lancet Oncol. 15(7):e279–e289. doi: https://doi.org/10.1016/S1470-2045(13)70567-9
   PubMed Web of Science ®Google Scholar
• Freund Y, Lemachatti N, Krastinova E, Van Laer M, Claessens YE, Avondo A, Occelli C, Feral-Pierssens AL, Truchot J, Ortega M, et al. 2017. Prognostic accuracy of sepsis-3 criteria for in-hospital mortality among patients with suspected infection presenting to the emergency department. Jama. 317(3):301–308. doi: https://doi.org/10.1001/jama.2016.20329
   PubMed Web of Science ®Google Scholar
• Guo J, Tao W, Tang D, Zhang J. 2017. Th17/regulatory T cell imbalance in sepsis patients with multiple organ dysfunction syndrome: attenuated by high-volume hemofiltration. Int J Artif Organs. 40(11):607–614. doi: https://doi.org/10.5301/ijao.5000625
   Google Scholar
• Harris HE, Andersson U, Pisetsky DS. 2012. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 8(4):195–202. doi: https://doi.org/10.1038/nrrheum.2011.222
   PubMed Web of Science ®Google Scholar
• Hotchkiss RS, Karl IE. 2003. The pathophysiology and treatment of sepsis. N Engl J Med. 348(2):138–150. doi: https://doi.org/10.1056/NEJMra021333
   PubMed Web of Science ®Google Scholar
• Kasten K, Seitz A, Unsinger J, Hildeman D, Hotchkiss R, Caldwell C. 2010. IL-7 promotes T cell viability, enhances immunity, and improves survival in sepsis. J Surg Res. 158(2):209–210. doi: https://doi.org/10.1016/j.jss.2009.11.114
   Google Scholar
• Kragstrup TW, Juul-Madsen K, Christiansen SH, Zhang X, Krog J, Vorup-Jensen T, Kjaergaard AG. 2017. Altered levels of soluble CD18 may associate immune mechanisms with outcome in sepsis. Clin Exp Immunol. 190(2):258–267. doi: https://doi.org/10.1111/cei.13016
   Google Scholar
• Lan KC, Chao SC, Wu HY, Chiang CL, Wang CC, Liu SH, Weng TI. 2017. Salidroside ameliorates sepsis-induced acute lung injury and mortality via downregulating NF-kappaB and HMGB1 pathways through the upregulation of SIRT1. Sci Rep. 7(1):12026. doi: https://doi.org/10.1038/s41598-017-12285-8
   PubMedGoogle Scholar
• Lee W, Ku SK, Bae JS. 2017. Zingerone reduces HMGB1-mediated septic responses and improves survival in septic mice. Toxicol Appl Pharmacol. 329:202–211. doi: https://doi.org/10.1016/j.taap.2017.06.006
   Google Scholar
• Lee W, Ku SK, Kim TH, Bae JS. 2013. Emodin-6-O-beta-D-glucoside inhibits HMGB1-induced inflammatory responses in vitro and in vivo. Food Chem Toxicol. 52:97–104. doi: https://doi.org/10.1016/j.fct.2012.10.061
   PubMed Web of Science ®Google Scholar
• Levy MM, Artigas A, Phillips GS, Rhodes A, Beale R, Osborn T, Vincent JL, Townsend S, Lemeshow S, Dellinger RP. 2012. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis. 12(12):919–924. doi: https://doi.org/10.1016/S1473-3099(12)70239-6
   PubMed Web of Science ®Google Scholar
• Mishnev OD, Grinberg LM, Zairatyants OV. 2016. Actual problems of the pathology of sepsis: 25 years in search of a consensus. Arkh Patol. 78(6):3–8. doi: https://doi.org/10.17116/patol20167863-8
   Google Scholar
• Muller L, Jaber S, Molinari N, Favier L, Larché J, Motte G, Lazarovici S, Jacques L, Alonso S, Leone M, et al. 2012. Fluid management and risk factors for renal dysfunction in patients with severe sepsis and/or septic shock. Crit Care. 16(1):R34. doi: https://doi.org/10.1186/cc11213
   Google Scholar
• Park EJ, Jang HJ, Tsoyi K, Kim YM, Park SW, Kim HJ, Lee JH, Chang KC, Deng JC. 2013. The heme oxygenase-1 inducer THI-56 negatively regulates iNOS expression and HMGB1 release in LPS-activated RAW 264.7 cells and CLP-induced septic mice. PLoS One. 8(10):e76293. doi: https://doi.org/10.1371/journal.pone.0076293
   Google Scholar
• Raghu A, Komorowski M, Celi LA, Szolovits P, Ghassemi M. 2017. Continuous state-space models for optimal sepsis treatment-a deep reinforcement learning approach. arXiv preprint.
   Google Scholar
• Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al. 2017. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 43(3):304–377. doi: https://doi.org/10.1007/s00134-017-4683-6
   PubMed Web of Science ®Google Scholar
• Sadaka F, EthmaneAbouElMaali C, Cytron MA, Fowler K, Javaux VM, O'Brien J. 2017. Predicting mortality of patients with sepsis: a comparison of APACHE II and APACHE III scoring systems. J Clin Med Res. 9(11):907–910. doi: https://doi.org/10.14740/jocmr3083w
   PubMedGoogle Scholar
• Shankar-Hari M. 2017. How could we enhance translation of sepsis immunology to inform immunomodulation trials in sepsis? Crit Care. 21(1):125. doi: https://doi.org/10.1186/s13054-017-1715-0
   Google Scholar
• Stevens NE, Chapman MJ, Fraser CK, Kuchel TR, Hayball JD, Diener KR. 2017. Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes. Sci Rep. 7(1):5850. doi: https://doi.org/10.1038/s41598-017-06205-z
   PubMedGoogle Scholar
• Tipoe TL, Wu WKK, Chung L, Gong M, Dong M, Liu T, Roever L, Ho J, Wong MCS, Chan MTV, et al. 2018. Plasminogen activator inhibitor 1 for predicting sepsis severity and mortality outcomes: a systematic review and meta-analysis. Front Immunol. 9:1218. doi: https://doi.org/10.3389/fimmu.2018.01218
   PubMed Web of Science ®Google Scholar
• Tiruvoipati R, Sultana N, Lewis D. 2012. Cardiac troponin I does not independently predict mortality in critically ill patients with severe sepsis. Emerg Med Australas. 24(2):151–158. doi: https://doi.org/10.1111/j.1742-6723.2011.01530.x
   Google Scholar
• Unsinger J, McGlynn M, Kasten KR, Hoekzema AS, Watanabe E, Muenzer JT, McDonough JS, Tschoep J, Ferguson TA, McDunn JE, et al. 2010. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J Immunol. 184(7):3768–3779. doi: https://doi.org/10.4049/jimmunol.0903151
   PubMed Web of Science ®Google Scholar
• Wang H, Cui Z, Sun F, Ding H. 2017. Glucan phosphate inhibits HMGB-1 release from rat myocardial H9C2 cells in sepsis via TLR4/NF-small ka, CyrillicB signal pathway. Clin Invest Med. 40(2):E66–E72. doi: https://doi.org/10.25011/cim.v40i2.28197
   Google Scholar